BiotechTube
Kyntra Bio

Kyntra Bio

Cambridge, United States· Est.
kyntrabio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5.2M

Overview

Kyntra Bio is a private, pre-revenue biotech founded in 2021 and headquartered in Cambridge, Massachusetts. The company is developing a focused pipeline of innovative therapies, with its lead programs being roxadustat (Phase 3-ready for LR-MDS anemia) and FG-3246 (Phase 2 for mCRPC). Under CEO Thane Wettig, Kyntra leverages in-licensed assets and a platform-agnostic approach to target key biological pathways in cancer and anemia, with initial clinical data for its ADC expected in 2026.

OncologyHematology

Technology Platform

Asset-centric development of therapies targeting key pathways: HIF-PH inhibition for anemia and CD46-targeting antibody-drug conjugates (ADCs) with companion PET imaging for oncology.

Funding History

1
Total raised:$5.2M
Seed$5.2M

Opportunities

Roxadustat addresses a high-unmet need in LR-MDS anemia for patients ineligible for ESAs, offering a convenient oral alternative to transfusions.
FG-3246 targets a novel antigen (CD46) in the large mCRPC market, with a companion imaging agent (FG-3180) enabling a precision medicine approach that could optimize patient selection and clinical outcomes.

Risk Factors

High clinical development risk as both lead programs are unproven in pivotal studies for these specific indications.
Financial risk is significant as a pre-revenue private company requiring substantial capital to fund Phase 3 and Phase 2 trials.
Competitive and regulatory risks are inherent in both the crowded mCRPC landscape and the niche LR-MDS anemia space.

Competitive Landscape

In LR-MDS anemia, roxadustat would compete against erythropoiesis-stimulating agents (ESAs) and transfusion support, aiming to serve the ESA-refractory population. In mCRPC, FG-3246 enters a crowded field with multiple approved therapies (e.g., PARP inhibitors, radioligands, chemotherapies, other ADCs) and would need to demonstrate superior efficacy or a favorable safety profile, potentially aided by its novel CD46 target and companion diagnostic.

More companies in Biologics / Biosimilars →More companies in United States →